Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11360MR)

This product GTTS-WQ11360MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11360MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14669MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ1798MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ1352MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-806
GTTS-WQ13140MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ2755MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ7258MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ11890MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ7808MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GS-HIV
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW